More Articles Back to Article
Capmatinib granted priority review as treatment for NSCLC
Priority review was granted by the FDA to Novartis' new drug application for its investigational drug INC280, or capmatinib, which is being assessed as a first-line treatment for patients diagnosed with locally advanced or metastatic MET exon 14 skipping mutated non-small cell lung cancer. Specialty Pharmacy Times (2/11)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!